Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Insights and Forecast to 2028

Report ID: 1548649 | Published Date: Jan 2025 | No. of Page: 109 | Base Year: 2024 | Rating: 3.9 | Webstory: Check our Web story
1 Study Coverage
    1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Introduction
    1.2 Market by Type
        1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Immune DTaP Vaccine
        1.2.3 Therapy DTaP Vaccine
    1.3 Market by Application
        1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Adult
        1.3.3 Pediatric
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Estimates and Forecasts 2017-2028
    2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Estimates and Forecasts 2017-2028
    2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
        2.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022)
        2.4.2 Global Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Region (2023-2028)
    2.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
        2.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022)
        2.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers
        3.1.1 Global Top Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers by Sales (2017-2022)
        3.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
    3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers
        3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2017-2022)
        3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2021
    3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
        4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales by Type (2017-2022)
        4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales by Type (2023-2028)
        4.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
    4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type
        4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Type (2017-2022)
        4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
    4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type
        4.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022)
        4.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
        5.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales by Application (2017-2022)
        5.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales by Application (2023-2028)
        5.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
    5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application
        5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Application (2017-2022)
        5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
    5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application
        5.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022)
        5.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
        6.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
        6.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
    6.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
        6.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
        6.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
    6.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
        6.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
        6.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
        7.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
        7.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
    7.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
        7.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
        7.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
    7.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
        7.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
        7.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
        8.1.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
        8.1.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
    8.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
        8.2.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
        8.2.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
    8.3 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
        8.3.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2028)
        8.3.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
        9.1.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
        9.1.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
    9.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
        9.2.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
        9.2.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
    9.3 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
        9.3.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
        9.3.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
        10.1.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
    10.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
        10.2.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
    10.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
        10.3.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Sanofi Pasteur
        11.1.1 Sanofi Pasteur Corporation Information
        11.1.2 Sanofi Pasteur Overview
        11.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Sanofi Pasteur Recent Developments
    11.2 GlaxoSmithKline
        11.2.1 GlaxoSmithKline Corporation Information
        11.2.2 GlaxoSmithKline Overview
        11.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 GlaxoSmithKline Recent Developments
    11.3 Protein Sciences Corporation
        11.3.1 Protein Sciences Corporation Corporation Information
        11.3.2 Protein Sciences Corporation Overview
        11.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Protein Sciences Corporation Recent Developments
    11.4 Novartis AG
        11.4.1 Novartis AG Corporation Information
        11.4.2 Novartis AG Overview
        11.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Novartis AG Recent Developments
    11.5 Seqirus
        11.5.1 Seqirus Corporation Information
        11.5.2 Seqirus Overview
        11.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Seqirus Recent Developments
    11.6 Merck Sharp & Dohme Corp
        11.6.1 Merck Sharp & Dohme Corp Corporation Information
        11.6.2 Merck Sharp & Dohme Corp Overview
        11.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Merck Sharp & Dohme Corp Recent Developments
    11.7 Astellas Pharma US
        11.7.1 Astellas Pharma US Corporation Information
        11.7.2 Astellas Pharma US Overview
        11.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Astellas Pharma US Recent Developments
    11.8 Pfizer Inc
        11.8.1 Pfizer Inc Corporation Information
        11.8.2 Pfizer Inc Overview
        11.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Pfizer Inc Recent Developments
    11.9 Johnson & Johnson
        11.9.1 Johnson & Johnson Corporation Information
        11.9.2 Johnson & Johnson Overview
        11.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Johnson & Johnson Recent Developments
    11.10 Lanzhou Institute of Biological Products Co., Ltd
        11.10.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
        11.10.2 Lanzhou Institute of Biological Products Co., Ltd Overview
        11.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
    11.11 AstraZeneca
        11.11.1 AstraZeneca Corporation Information
        11.11.2 AstraZeneca Overview
        11.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 AstraZeneca Recent Developments
    11.12 Emergent BioSolutions Inc
        11.12.1 Emergent BioSolutions Inc Corporation Information
        11.12.2 Emergent BioSolutions Inc Overview
        11.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 Emergent BioSolutions Inc Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Chain Analysis
    12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
    12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Marketing
        12.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels
        12.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
    12.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
    13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
    13.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
    13.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
14 Key Findings in The Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
List of Tables
    Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Immune DTaP Vaccine
    Table 3. Major Manufacturers of Therapy DTaP Vaccine
    Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
    Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
    Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
    Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2023-2028)
    Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2022)
    Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2023-2028)
    Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
    Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Manufacturers (2017-2022)
    Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers (2017-2022)
    Table 18. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
    Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2021)
    Table 21. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
    Table 23. Date of Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2017-2022)
    Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2023-2028)
    Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2017-2022)
    Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2023-2028)
    Table 33. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022) & (USD/Dose)
    Table 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2023-2028) & (USD/Dose)
    Table 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2017-2022)
    Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2023-2028)
    Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2017-2022)
    Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2023-2028)
    Table 43. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022) & (USD/Dose)
    Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
    Table 45. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 46. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 47. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 48. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 49. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 50. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 51. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 52. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 53. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 54. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 55. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 56. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 57. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 58. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 59. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 60. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 61. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 62. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 63. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 64. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 65. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 66. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 67. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 68. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 69. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 70. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 71. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 72. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 74. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 75. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
    Table 78. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
    Table 79. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 81. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 82. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 83. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 84. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 85. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 86. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 87. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 88. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 89. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 90. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 91. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 92. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 93. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 94. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 95. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 96. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 98. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 99. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 102. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 103. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 105. Sanofi Pasteur Corporation Information
    Table 106. Sanofi Pasteur Description and Major Businesses
    Table 107. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 108. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 109. Sanofi Pasteur Recent Developments
    Table 110. GlaxoSmithKline Corporation Information
    Table 111. GlaxoSmithKline Description and Major Businesses
    Table 112. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 113. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. GlaxoSmithKline Recent Developments
    Table 115. Protein Sciences Corporation Corporation Information
    Table 116. Protein Sciences Corporation Description and Major Businesses
    Table 117. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 118. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Protein Sciences Corporation Recent Developments
    Table 120. Novartis AG Corporation Information
    Table 121. Novartis AG Description and Major Businesses
    Table 122. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 123. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Novartis AG Recent Developments
    Table 125. Seqirus Corporation Information
    Table 126. Seqirus Description and Major Businesses
    Table 127. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 128. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Seqirus Recent Developments
    Table 130. Merck Sharp & Dohme Corp Corporation Information
    Table 131. Merck Sharp & Dohme Corp Description and Major Businesses
    Table 132. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 133. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Merck Sharp & Dohme Corp Recent Developments
    Table 135. Astellas Pharma US Corporation Information
    Table 136. Astellas Pharma US Description and Major Businesses
    Table 137. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 138. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Astellas Pharma US Recent Developments
    Table 140. Pfizer Inc Corporation Information
    Table 141. Pfizer Inc Description and Major Businesses
    Table 142. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 143. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Pfizer Inc Recent Developments
    Table 145. Johnson & Johnson Corporation Information
    Table 146. Johnson & Johnson Description and Major Businesses
    Table 147. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 148. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Johnson & Johnson Recent Developments
    Table 150. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
    Table 151. Lanzhou Institute of Biological Products Co., Ltd Description and Major Businesses
    Table 152. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 153. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 154. Lanzhou Institute of Biological Products Co., Ltd Recent Developments
    Table 155. AstraZeneca Corporation Information
    Table 156. AstraZeneca Description and Major Businesses
    Table 157. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 158. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 159. AstraZeneca Recent Developments
    Table 160. Emergent BioSolutions Inc Corporation Information
    Table 161. Emergent BioSolutions Inc Description and Major Businesses
    Table 162. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 163. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 164. Emergent BioSolutions Inc Recent Developments
    Table 165. Key Raw Materials Lists
    Table 166. Raw Materials Key Suppliers Lists
    Table 167. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
    Table 168. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List
    Table 169. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
    Table 170. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
    Table 171. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
    Table 172. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
    Table 173. Research Programs/Design for This Report
    Table 174. Key Data Information from Secondary Sources
    Table 175. Key Data Information from Primary Sources
List of Figures
    Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Picture
    Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Type in 2021 & 2028
    Figure 3. Immune DTaP Vaccine Product Picture
    Figure 4. Therapy DTaP Vaccine Product Picture
    Figure 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Application in 2021 & 2028
    Figure 6. Adult
    Figure 7. Pediatric
    Figure 8. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Report Years Considered
    Figure 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2028 (K Doses)
    Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2028 (US$ Million)
    Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
    Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2023-2028)
    Figure 15. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 16. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 17. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 18. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 19. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 20. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 22. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 24. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 26. The Top 5 and 10 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in the World: Market Share by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2021
    Figure 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
    Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
    Figure 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
    Figure 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
    Figure 32. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
    Figure 33. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
    Figure 34. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
    Figure 35. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
    Figure 36. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
    Figure 37. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
    Figure 38. U.S. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 39. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 40. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
    Figure 41. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
    Figure 42. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
    Figure 43. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
    Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
    Figure 45. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
    Figure 46. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 47. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 48. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 49. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 50. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 51. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
    Figure 52. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
    Figure 53. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
    Figure 54. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
    Figure 55. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Region (2017-2028)
    Figure 56. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Region (2017-2028)
    Figure 57. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 58. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 59. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 60. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 61. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 62. Taiwan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 63. Indonesia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 64. Thailand Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 65. Malaysia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 66. Philippines Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 67. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
    Figure 68. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
    Figure 69. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
    Figure 70. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
    Figure 71. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
    Figure 72. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
    Figure 73. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 74. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 75. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 76. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
    Figure 77. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
    Figure 78. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
    Figure 79. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
    Figure 80. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
    Figure 81. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
    Figure 82. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 83. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 84. U.A.E Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 85. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain
    Figure 86. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Process
    Figure 87. Channels of Distribution
    Figure 88. Distributors Profiles
    Figure 89. Bottom-up and Top-down Approaches for This Report
    Figure 90. Data Triangulation
    Figure 91. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Frequently Asked Questions
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Disability Insurance

Disability Insurance market is segmented by players, region (country), by Type and by Application ... Read More

Forage Sorghum Seed

Forage Sorghum Seed market is segmented by Type and by Application. Players, stakeholders, and ot ... Read More